University of South Florida

The United States Government As Represented by the Department of Veterans Affairs

University of Texas System

Cryo-cell International, Inc.

Medical College of Georgia

Office Of General Counsel—psg Iv (024)

Cesario V Borlongan

Paul R Sanberg

Don F Cameron

Samuel Saporta

Richard M Heller

Niketa A Patel

Svitlana Garbuzova-Davis

Paula Cole Bickford

Denise Ratzlaff Cooper

Donald Eugene Moss

Lisa Gould

Carmelina Gemma

Fernando L Vale

Peter Richard Nelson

Agneta Othberg

Julie Allickson

Isabel C Sumaya

Harry Ronald Van Loveren

Blood brain barrier (BBB) permeabilizers, such as mannitol, can facilitate the entry of stem cells from the periphery to the stroke brain. It is unknown whether BBB permeation in the chronic stage of the disease still facilitates the entry of stem cells from the periphery to the injured brain. Evidence herein shows BBB permeation in the chronic stage of stroke assisted in the entry of stem cells from the periphery to the stroke brain. Stroke models treated with human umbilical cord stem cells (hUCBC) only (2 million viable cells), mannitol or a combination. Results revealed that hUCBC alone or combined with mannitol displayed significant behavioral and histological deficits compared to control animals, with the HUCBC-mannitol combined treatment showing improvements over hUCBC only treatments in brain cell survival in the peri-infarct area. BBB permeation in chronic stroke also lowers the effective stem cell dose necessary to improve functional outcomes.

Method of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers

Provided herein is a method of diagnosing or prognosing an epilepsy or epilepsy-related disorder. Also provided herein is a method of treating an epilepsy or epilepsy-related disorder. Further provided are non-epileptic and epileptic neural stem cells and cell cultures.

Methods of treating epilepsy using neural stem cells that express nanog, SSEA-4, OCT-4, MIR-34B, MIR-34C and MIR-592

Most spinal cord therapies are administered systemically, with only a small portion of the therapeutic reaching the spinal cord. A novel method for delivering therapeutics directly to the spinal cord is provided. The method uses a dual balloon catheter to isolate the microvasculature around a region of the spinal cord. Once isolated, one or more therapeutics are delivered directly to the spinal cord blood supply. This allows for smaller, safer therapeutic dose to be utilized.

Non-invasive method for direct delivery of therapeutics to the spinal cord in the treatment of spinal cord pathology

A combined therapy of human umbilical cord blood cells (hUCB) and G-CSF at the acute stage of TBI was tested as a therapeutic for progressive secondary effects of chronic TBI. Rats were treated with saline carrier, or therapeutic in carrier as follows; G-CSF, hUCB, or hUCB and G-CSF, 7-days after TBI. Eight weeks later, behavioral testing was performed and brains harvested to analyze hippocampal cell loss, neuroinflammatory response, and neurogenesis. Results revealed that the monotherapies partially suppressed neuroinflammation and reduced hippocampal cell loss. However, combined therapy of hUCB and G-CSF robustly dampened neuroinflammation, while enhancing endogenous neurogenesis and reducing hippocampal cell loss. Vigorous and long-lasting recovery of motor function accompanied the combined therapy, which was either moderately or short-lived in the monotherapy conditions. These results suggest that combined treatment rather than monotherapy appears optimal for abrogating histophalogical and motor impairments in chronic TBI.

Combination therapy of stem cell mobilizing agents and stem cell transplantation

A method of treating traumatic brain injury (TBI) and other neurological disorders is presented herein. Both conditioned media (CM) containing long non-coding RNAs such as NEAT1 (nuclear enriched abundant transcript 1) and MALAT1 (metastasis associated lung adenocarcinoma transcript 1) as well as human adipose-derived stem cells (hADSCs) themselves (Tx), when administered at least 3 hours post injury, were found to significantly ameliorate motor and cognitive functions in young, but not aged, mice undergoing TBI. Significant reduction in cortical damage and hippocampal cell loss was observed in both Tx and CM groups in young rats, whereas less neuroprotection was detected in the aged rats and mainly in the Tx group but not the CM group, which may in part result from decreased homing of the cells to the spleen.

Method of treating neurological disorders using long non-coding RNAs

A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stem cell phenotypic markers and neuronal phenotypic markers under appropriate conditioned media. Oxygen glucose deprivation stroke models show that OGD-exposed primary rat neurons, co-cultured with menstrual blood-derived stem cells or exposed to the media from cultured menstrual blood, exhibited significantly reduced cell death. Transplantation of menstrual blood-derived stem cells, either intracerebrally or intravenously, after experimentally induced ischemic stroke in adult rats also significantly reduced behavioral and histological impairments compared to vehicle-infused rats.

Methods of treating stroke using stem cell-like menstrual blood cells

The present invention provides for methods of treating cognitive deficits resulting from interruption of blood supply and/or oxygen deficit by administering a therapeutically effective dose of a sulfonyl fluoride, such as methanesulfonyl fluoride and ethanesulfonyl fluoride. The underlying cause of the or oxygen deficit can be from stroke, trauma, carbon monoxide poisoning, and other poisonings. This method also includes co-administering with sulfonyl fluoride with a therapeutically effective dose of a second agent.

Methods of attenuating cognitive deficits with sulfonyl fluorides

The present invention provides compositions and methods for enhancing the neuroprotective effect of umbilical cord blood cells. More particularly, the present invention provides methods of treating neurodegenerative disorders by administering umbilical cord blood cells and a substance capable of permeabilizing the blood brain barrier. In one embodiment, the blood brain barrier permeabilizer is mannitol. In another embodiment, the blood brain barrier permeabilizer is Cereport.

Methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers

A method of producing a sustained localized immunosuppressive effect in localized tissues is achieved by transplanting Sertoli cells proximate to the tissue.

Sertoli cells as transplantation facilitator for cell transplantation

A method of enhancing the viability of cryopreserved cells is culturing Sertoli cells in media to produce preconditioned media and adding the preconditioned media to the cells to be cryopreserved. The cells are then cryopreserved. Alternatively, a method of enhancing the viability of cryopreserved cells is co-culturing Sertoli cells and cells to be cryopreserved in media and cryopreserving both.

Method and media for enhancing cryopreservation of cells

Sertoli cells as neurorecovery inducing cells for neurodegenerative

A method to increase viability, number, survival and maturation of cells for transplantation or cryopreservation by culturing the cells with Sertoli cells or with sertoli-cell conditioned media (SCM) prior to transplantation (pre-culturing) or cryopreservation.

Method and media for enhancing viability maturation, and

A method of producing a sustained localized brain immunosuppressive effect in localized tissues is achieved by transplanting Sertoli cells proximate to the brain tissue.

A method of generating in situ trophic factor production by transplanting Sertoli cells into the central nervous system of a mammal, the cells creating trophic factors in situ.

Growing community of inventors

Odessa, FL, United States of America

Cesario V Borlongan